STOCK TITAN

Bio-Techne Corp (TECH) CFO exercises 62,068 options, 51,024 shares withheld

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bio-Techne Corp CFO James Hippel exercised stock options covering 62,068 shares of common stock on July 29, 2026 at an exercise price of $47.60 per share. A separate Form 4 entry shows 51,024 shares of common stock disposed of at $72.03 per share, designated as payment of exercise price or tax liability by withholding securities. He continues to hold multiple option and restricted stock unit awards, including options over 167,328 shares at an exercise price of $66.97 expiring August 5, 2027.

Positive

  • None.

Negative

  • None.
Insider Hippel James
Role CFO
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) F1 62,068 $0.00 $0.00
Exercise Common Stock 62,068 $47.60 $2.95M
Exercise Price or Tax Liability Common Stock 51,024 $72.03 $3.68M
holding Stock Options (Right to Buy) F1 -- -- --
holding Stock Options (Right to Buy) F1 -- -- --
holding Stock Options (Right to Buy) F3 -- -- --
holding Performance Restricted Stock Units F2, F4 -- -- --
holding Performance Stock Options (Right to Buy) F4 -- -- --
holding Stock Options (Right to Buy) F5 -- -- --
holding Performance Restricted Stock Units F2, F6 -- -- --
holding Restricted Stock Units F2, F7 -- -- --
holding Stock Options (Right to Buy) F8 -- -- --
holding Restricted Stock Units F2, F9 -- -- --
holding Performance Restricted Stock Units F2, F10 -- -- --
holding Restricted Stock Units F2, F11 -- -- --
holding Stock Options (Right to Buy) F12 -- -- --
Holdings After Transaction: Stock Options (Right to Buy) — 369,056 shares (Direct); Common Stock — 164,714 shares (Direct); Performance Restricted Stock Units — 67,347 shares (Direct); Performance Stock Options (Right to Buy) — 37,314 shares (Direct); Restricted Stock Units — 41,809 shares (Direct)
Footnotes (12)
  1. F1. Fully exercisable.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
  3. F3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
  4. F4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  5. F5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
  6. F6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  7. F7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
  8. F8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
  9. F9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
  10. F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  11. F11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
  12. F12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Options exercised 62068.0000 shares Stock options exercised by CFO James Hippel on 2026-07-29
Option exercise price 47.6000 per share Exercise price for 62,068 stock options converted into common stock
Shares withheld for exercise price or taxes 51024.0000 shares Common shares disposed of at $72.03 under code F for payment of exercise price or tax liability
Withholding transaction price 72.0300 per share Per-share value used for 51,024-share withholding disposition
Remaining options at $66.97 167328.0000 underlying shares Stock options with $66.9700 exercise price expiring 2027-08-05
Performance stock options at $84.61 37314.0000 underlying shares Performance stock options expiring 2030-08-15
Restricted Stock Units position 23089.0000 underlying shares Restricted Stock Units with vesting in 2026 and 2027 per footnote F9
Performance Restricted Stock Units financial
"Security title listed as "Performance Restricted Stock Units" with common stock underlying"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Restricted Stock Units financial
"Footnote states each restricted stock unit represents a contingent right to one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Stock Options (Right to Buy) financial
"Derivative holding described as "Performance Stock Options (Right to Buy)" with exercise price"
exercise price financial
"Transaction code description references payment of exercise price or tax liability"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
tax liability financial
"Disposition coded F is for payment of exercise price or tax liability by withholding securities"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did BIO-TECHNE Corp (TECH) CFO James Hippel report in this Form 4?

CFO James Hippel reported exercising 62,068 stock options for Bio-Techne common stock at an exercise price of $47.60 per share. A related entry shows 51,024 shares disposed of at $72.03 per share as payment of exercise price or tax liability.

How many BIO-TECHNE (TECH) options did the CFO exercise and at what price?

Hippel exercised stock options covering 62,068 shares of Bio-Techne common stock at an exercise price of $47.60 per share. The options were fully exercisable and were scheduled to expire on August 7, 2026 before this exercise.

What does the 51,024-share disposition mean in the BIO-TECHNE (TECH) Form 4?

The Form 4 reports a disposition of 51,024 common shares at $72.03 per share, coded "F". The description states this entry represents payment of exercise price or tax liability by delivering or withholding securities, not an open-market sale.

What BIO-TECHNE (TECH) equity awards does the CFO still hold after this transaction?

Hippel remains entitled to various equity awards, including stock options over 167,328 shares at an exercise price of $66.97 expiring August 5, 2027, plus additional options and restricted stock units and performance units over tens of thousands of Bio-Techne shares.

Are performance-based awards included in the BIO-TECHNE (TECH) CFO’s holdings?

Yes. The holdings include Performance Restricted Stock Units and Performance Stock Options, such as units over 13,865 and 24,062 shares. Related footnotes state these awards vest in full or in part if specified performance goals are achieved by future vesting dates.

Does the BIO-TECHNE (TECH) Form 4 show any remaining restricted stock units for the CFO?

Yes. The filing lists several Restricted Stock Unit positions, including blocks of 4,010, 23,089 and 14,710 underlying shares. Footnotes detail scheduled vesting dates in 2026, 2027 and 2028, each unit converting into one Bio-Techne common share upon vesting.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hippel James

(Last)(First)(Middle)
614 MCKINLEY PLACE NE

(Street)
MINNEAPOLIS MINNESOTA 55413

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/29/2026M62,068A$47.6215,738D
Common Stock07/29/2026F51,024D$72.03164,714D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$47.607/29/2026M62,068 (1)08/07/2026Common Stock62,068$00D
Stock Options (Right to Buy)$66.97 (1)08/05/2027Common Stock167,328167,328D
Stock Options (Right to Buy)$120.46 (1)08/06/2028Common Stock40,53640,536D
Stock Options (Right to Buy)$94.52 (3)08/15/2029Common Stock45,22045,220D
Performance Restricted Stock Units(2) (4) (4)Common Stock13,86513,865D
Performance Stock Options (Right to Buy)$84.61 (4)08/15/2030Common Stock37,31437,314D
Stock Options (Right to Buy)$84.61 (5)08/15/2030Common Stock45,92345,923D
Performance Restricted Stock Units(2) (6) (6)Common Stock24,06224,062D
Restricted Stock Units(2) (7) (7)Common Stock4,0108,021D
Stock Options (Right to Buy)$74.91 (8)08/15/2034Common Stock32,41732,417D
Restricted Stock Units(2) (9) (9)Common Stock23,08923,089D
Performance Restricted Stock Units(2) (10) (10)Common Stock29,42029,420D
Restricted Stock Units(2) (11) (11)Common Stock14,71014,710D
Stock Options (Right to Buy)$53.6 (12)08/15/2035Common Stock37,63237,632D
Explanation of Responses:
1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed07/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)